https://www.sarepta.com/
Sarepta Therapeutics | Biopharmaceutical Company for Rare Diseases
We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases. Learn more about Sarepta.
sarepta therapeuticsbiopharmaceutical companyrarediseases
https://health.economictimes.indiatimes.com/tag/sarepta+therapeutics+inc
Sarepta therapeutics inc - Latest sarepta therapeutics inc , Information & Updates - Health -ET...
ETHealthworld.com brings latest sarepta therapeutics inc news, views and updates from all top sources for the Indian Health industry.
sarepta therapeuticslatest informationincupdateshealth
https://www.sareptatherapeutics.ch/
Sarepta Therapeutics | Biopharmaceutical Company for Rare Diseases
We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases. Learn more about Sarepta.
sarepta therapeuticsbiopharmaceutical companyrarediseases
https://pharma.economictimes.indiatimes.com/news/pharma-industry/arrowhead-pharmaceuticals-expects-near-term-payments-from-sarepta-despite-crisis/122861187
Sarepta Therapeutics: Arrowhead Pharmaceuticals Expects Near-Term Payments from Sarepta Despite...
Arrowhead Pharmaceuticals anticipates receiving milestone payments from Sarepta Therapeutics, despite setbacks including a death in a clinical trial and a...
sarepta therapeuticsarrowheadpharmaceuticalsexpectsnear
https://www.fool.com/investing/general/2016/01/15/why-intel-sarepta-therapeutics-and-sprint-slumped.aspx
Why Intel, Sarepta Therapeutics, and Sprint Slumped Today | The Motley Fool
Jan 15, 2016 - These stocks were particularly poor performers in a plunging market Friday. Find out why.
sarepta therapeuticsintel
https://zertifikate.morganstanley.com/produktdetails/de000mm09f14
DE000MM09F14 | MM09F1 | Discount-Zertifikat | Sarepta Therapeutics | 20,00 | 18.06.26 | Morgan...
DE000MM09F14 | MM09F1 | Discount-Zertifikat | Sarepta Therapeutics | 20,00 | 18.06.26 - Finden Sie Zertifikate und Optionsscheine von Morgan Stanley.
sarepta therapeutics
https://www.businesswire.com/news/home/20250813527219/en/Sarepta-Therapeutics-Announces-Advancement-of-siRNA-Collaboration-and-Sale-of-Arrowhead-Equity-Investment
Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has sold 9,265,312 shares of co...
sarepta therapeuticsannouncesadvancement
https://www.benzinga.com/quote/SRPT/news
Latest Sarepta Therapeutics Stock News | NASDAQ:SRPT | Benzinga
Get the latest news on Sarepta Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on SRPT performance
sarepta therapeuticsstock newslatestnasdaqbenzinga
https://www.businesswire.com/news/home/20260331816781/en/Sarepta-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previ...
sarepta therapeutics
https://www.businesswire.com/news/home/20250506808800/en/Sarepta-Therapeutics-Announces-First-Quarter-2025-Financial-Results-and-Recent-Corporate-Developments
Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter ...
sarepta therapeuticsfirst quarterfinancial resultsannounces
https://www.fool.com/investing/2017/05/01/how-much-would-sarepta-therapeutics-fetch-in-a-buy.aspx
How Much Would Sarepta Therapeutics Fetch in a Buyout? | The Motley Fool
May 1, 2017 - If Sarepta is up for sale, it could fetch a handsome premium. Here's why.
how muchsarepta therapeutics
https://www.benzinga.com/analyst-ratings/23/11/35572251/analyst-ratings-for-sarepta-therapeutics
Analyst Ratings for Sarepta Therapeutics - Sarepta Therapeutics (NASDAQ:SRPT) - Benzinga
analyst ratingssarepta therapeuticsnasdaqbenzinga
https://www.fool.com/investing/2018/01/09/why-sarepta-therapeutics-stock-doubled-in-2017.aspx
Why Sarepta Therapeutics Stock Doubled in 2017 | The Motley Fool
Jan 9, 2018 - Sarepta's new Duchenne muscular dystrophy drug burst onto the scene in 2017.
sarepta therapeuticsstockdoubledmotleyfool
https://pharma.economictimes.indiatimes.com/tag/sarepta+therapeutics+dmd+gene+therapy
Sarepta therapeutics dmd gene therapy - Latest sarepta therapeutics dmd gene therapy , Information...
ETPharma.com brings latest sarepta therapeutics dmd gene therapy news, views and updates from all top sources for the Indian Pharma industry.
sarepta therapeuticsgene therapydmdlatestinformation
https://www.nasdaq.com/market-activity/stocks/srpt
Sarepta Therapeutics, Inc. Common Stock (DE) (SRPT) Stock Price, Quote, News & History | Nasdaq
Discover real-time Sarepta Therapeutics, Inc. Common Stock (DE) (SRPT) stock prices, quotes, historical data, news, and Insights for informed trading and...
sarepta therapeuticscommon stock
https://www.businesswire.com/news/home/20230523006142/en/Sarepta-Therapeutics-Announces-Update-on-Regulatory-Review-of-SRP-9001
Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today provided the following update on the Biologics L...
sarepta therapeuticsregulatory reviewannouncesupdatesrp
https://www.fool.com/investing/2016/09/15/heres-why-sarepta-therapeutics-inc-is-falling-toda.aspx
Here's Why Sarepta Therapeutics Inc. is Falling Today | The Motley Fool
Sep 15, 2016 - A negative analyst note causes traders to flee.
sarepta therapeutics
https://www.prnewswire.com/news-releases/hansa-biopharma-and-partner-sarepta-therapeutics-plan-to-initiate-a-clinical-study-with-imlifidase-as-a-pre-treatment-to-sareptas-srp-9001-gene-therapy-in-dmd-in-2023-301667075.html
Hansa Biopharma and partner Sarepta Therapeutics plan to initiate a clinical study with imlifidase...
/PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that...
https://www.fool.com/investing/2016/05/25/heres-why-sarepta-therapeutics-stock-is-surging-hi.aspx
Here's Why Sarepta Therapeutics' Stock Is Surging Higher Today | The Motley Fool
May 25, 2016 - The FDA isn't quite ready to issue a final decision on Sarepta's controversial Duchenne muscular dystrophy drug.
https://prais.paho.org/en/fda-requests-sarepta-therapeutics-suspend-distribution-of-elevidys-and-places-clinical-trials-on-hold-for-multiple-gene-therapy-products-following-3-deaths/
FDA Requests Sarepta Therapeutics Suspend Distribution of Elevidys and Places Clinical Trials on...
https://markets.businessinsider.com/news/stocks/analysts-offer-insights-on-healthcare-companies-sarepta-therapeutics-srpt-and-livanova-livn-1035947982
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and LivaNova (LIVN) |...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT) and LivaNova (LIVN).Claim 70% Off...
healthcare companies
https://www.benzinga.com/news/23/03/31120648/sarepta-therapeutics-to-rally-over-53-here-are-10-other-analyst-forecasts-for-wednesday
Sarepta Therapeutics To Rally Over 53%? Here Are 10 Other Analyst Forecasts For Wednesday - Advance...
Mar 1, 2023 - Keybanc raised the price target for Ambarella, Inc. (NASDAQ: AMBA) from $95 to $105. Keybanc analyst John Vinh maintained an Overweight rating. Ambarella...
https://www.fool.com/investing/general/2015/10/06/sarepta-therapeutics-vs-biomarin-pharmaceutical-wh.aspx
Sarepta Therapeutics vs. BioMarin Pharmaceutical: Which Company Will Win the DMD Race? | The Motley...
Oct 6, 2015 - Which of these two companies will win the race to successfully develop the first Duchenne muscular dystrophy treatment? Our team of contributors weigh in.
https://www.fool.com/investing/2024/02/28/is-it-too-late-to-buy-sarepta-therapeutics-stock/
Is It Too Late to Buy Sarepta Therapeutics Stock? | The Motley Fool
Feb 28, 2024 - The company's hyperfocus on its core area could continue to be highly lucrative.
too late